Objective To determine maternal and neonatal outcomes in pregnant women with COVID-19 Design Retrospective, descriptive study Setting A single-center managing pregnant women with COVID-19 Population or Sample Third-trimester pregnant women with a diagnosis of COVID-19 Methods A retrospective, single-center, descriptive study Main Outcome Measures The maternal and neonatal results of COVID-19 pregnant women were evaluated by looking at the following parameters: the concentrations of D-dimer, complete blood count, ferritin, C-reactive protein, lymphocytes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), neonatal umbilical blood gas analyzes, real-time RT-PCR tests, lung CT imaging, admission to (neonatal) intensive care unit. Results In the third trimester, 40 pregnant women with COVID-19 were included. The most common complaint was cough (50%). The most common symptom that accompanied cough was fever and shortness of breath. Thirty-four patients delivered by cesarean and 6 patients delivered vaginally. Two patients were taken to the intensive care unit because of respiratory distress. There were no maternal and fetal deaths. The patients were hospitalized for an average of 5 days. One patient was followed up without treatment, while all other patients were given hydroxychloroquine. In addition, azithromycin, oseltamivir, or lopinavir/ritonavir were added to some patients in addition to hydroxychloroquine. Conclusions The clinical features of pregnant women with COVID-19 are comparable compared to non-pregnant adults. Long-term results and comparative studies are needed in this regard.